End-of-day quote
Mexican S.E.
03:30:00 08/05/2024 am IST
5-day change
1st Jan Change
17.36
MXN
+0.81%
+3.89%
+22.60%
Presentation Operator MessageOperator (Operator)Greetings, ladies and gentlemen. Thank you for...
This article is reserved for subscribers
Signed up already?
Log In Not subscribed yet?
Subscribe
Transcript : Genomma Lab Internacional, S.A.B. de C.V., Q1 2024 Earnings Call, Apr 25, 2024
25/04
Genomma Lab Internacional, S.A.B. de C.V. Reports Earnings Results for the First Quarter Ended March 31, 2024
24/04
CI
Genomma Lab Internacional, S.A.B. De C.V. Declares Cash Dividend
14/03
CI
Transcript : Genomma Lab Internacional, S.A.B. de C.V., Q4 2023 Earnings Call, Feb 22, 2024
22/02
Genomma Lab Internacional, S.A.B. de C.V. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
21/02
CI
Genomma Lab Internacional, S.A.B. de C.V. Reports Earnings Results for the Full Year Ended December 31, 2023
21/02
CI
Genomma Lab Internacional, S.A.B. De C.V. Announces Sixth Dividend Payment
14/12
CI
Procaps Group and Genomma Lab Announce Strategic Agreement to Manufacture and Market Softgel Products in Latin America
30/11
CI
Transcript : Genomma Lab Internacional, S.A.B. de C.V., Q3 2023 Earnings Call, Oct 26, 2023
26/23/26
Genomma Lab Internacional, S.A.B. de C.V. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
25/23/25
CI
Transcript : Genomma Lab Internacional, S.A.B. de C.V., Q2 2023 Earnings Call, Jul 27, 2023
27/23/27
Genomma Lab Internacional, S.A.B. de C.V. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
26/23/26
CI
Transcript : Genomma Lab Internacional, S.A.B. de C.V., Q1 2023 Earnings Call, Apr 27, 2023
27/23/27
Genomma Lab Internacional, S.A.B. de C.V. Reports Earnings Results for the First Quarter Ended March 31, 2023
27/23/27
CI
Transcript : Genomma Lab Internacional, S.A.B. de C.V. - Analyst/Investor Day
08/23/08
Transcript : Genomma Lab Internacional, S.A.B. de C.V., Q4 2022 Earnings Call, Feb 23, 2023
23/23/23
Genomma Lab Internacional, S.A.B. de C.V. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022
22/23/22
CI
Genomma Lab Internacional, S.A.B. de C.V. Reports Earnings Results for the Full Year Ended December 31, 2022
22/23/22
CI
IFC and Genomma Lab Sign Multi-Currency Long-Term Loan to Boost Access to OTC Medicines in Latin America and the Caribbean Region
10/23/10
CI
Genomma Lab Internacional, S.A.B. de C.V. Announces CEO Changes
28/22/28
CI
Genomma Lab Internacional, S.A.B. de C.V. Announces Management Changes
28/22/28
CI
Transcript : Genomma Lab Internacional, S.A.B. de C.V., Q3 2022 Earnings Call, Oct 27, 2022
27/22/27
Genomma Lab Internacional, S.A.B. De C.V. Cash Dividend
27/22/27
CI
Genomma Lab Internacional, S.A.B. de C.V. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
26/22/26
CI
Tranche Update on Genomma Lab Internacional, S.A.B. de C.V. (BMV:LAB B)'s Equity Buyback Plan announced on March 20, 2013.
26/22/26
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
Genomma Lab Internacional SAB de CV is a Mexico-based over-the-counter pharmaceutical (OTC pharmaceutical), generic drugs (GD) and personal care products company. The Company is engaged in the development, distribution and marketing of a range of products within different brands, for such treatments as anti-acne, varicose vein, hair loss, sexual stimulation and influenza; as well as analgesics and antifungals. The Companyâs product portfolio includes such brands as Asepxia, Cicatricure, Goicoechea, Bengue, Diabet TX, Genoprazol, Goicotabs, Shot B, SilkaMedic, Siluet 40, Nikzon, X Ray, Next, Touch Me, Lomecan V and QG5, among others. The Company is a parent of a number of controlled entities, which have operations established in Mexico, the United States, Peru, Chile, Ecuador and Honduras, among others. In June 2014, the Company acquired 50% stake in Grupo Comercial e Industrial Marzam SA de CV.
More about the company
Last Close Price
17.36
MXN
Average target price
19.46
MXN
Spread / Average Target
+12.08%
Consensus
1st Jan change
Capi.
+22.60% 937M +32.95% 700B +26.51% 569B -4.97% 358B +18.83% 330B +3.54% 287B +15.70% 236B +6.68% 202B -9.08% 197B +6.70% 161B
Other Pharmaceuticals
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1